Business Context and Reporting Period
This Form 8-K is filed by Eterna Therapeutics Inc. (trading symbol: ERNA) on September 17, 2024. The report addresses a critical corporate governance event regarding the company's continued listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the company's failure to meet the Minimum Stockholders' Equity Rule (Nasdaq Listing Rule 5550(b)(1)), which requires stockholders' equity of at least $2.5 million. The company previously reported equity below this threshold as of December 31, 2023.
Material Changes
- Loss of Compliance Extension: On September 17, 2024, Nasdaq staff determined that Eterna Therapeutics failed to regain compliance with the Minimum Stockholders' Equity Rule by the September 16, 2024 deadline.
- Imminent Delisting Risk: Unless an appeal is filed by September 24, 2024, trading of the company's common stock is scheduled to be suspended on September 26, 2024, followed by the filing of a Form 25-NSE to remove the securities from Nasdaq.
Outlook, Risks, and Management Commentary
Management intends to timely submit a request for a hearing with the Nasdaq Hearings Panel to appeal the staff's determination. A timely hearing request will stay the suspension of trading and the delisting filing pending the panel's decision.
- Timeline: Hearings are typically scheduled 30 to 45 days after the request, with decisions issued within 30 days of the hearing.
- Risks: There is no assurance the company will be successful at the hearing or maintain its listing. The company notes that a shorter-than-expected timeline for the hearing or decision could be unfavorable.
- Forward-Looking Statements: The report cautions investors against placing undue reliance on statements regarding the timing of the hearing and the panel's decision.
Investor Verification Checklist
- Verify if Eterna Therapeutics has filed a formal appeal with the Nasdaq Hearings Panel by the September 24, 2024 deadline.
- Monitor for the filing of Form 25-NSE, which would confirm the removal of the stock from Nasdaq listing.
- Review the company's most recent financial statements to assess the current stockholders' equity position relative to the $2.5 million requirement.
- Check for any subsequent announcements regarding the scheduling of the hearing or the panel's final decision.